Industry Overview

UK prostate cancer diagnosis & treatment market was valued at $845.5 million in 2025 and is projected to reach $1,971.3 million by 2035, growing at a CAGR of 8.9% during the forecast period (2026-2035). The market is growing due to the increasing incidence of prostate cancer, particularly among the aging male population. Rising awareness regarding early screening through prostate-specific antigen testing and digital rectal examination is contributing to higher diagnosis rates. Continuous advancements in diagnostic technologies and imaging accuracy are improving early detection and risk stratification. Expanding availability of advanced therapeutic options, including immunotherapy and targeted therapy, is enhancing treatment outcomes and patient survival. In addition, supportive reimbursement frameworks and strengthening oncology infrastructure across emerging and developed economies are reinforcing sustained market expansion.

Market Dynamics

Rising Disease Burden and Expanding Diagnostic Adoption

The rising incidence of prostate cancer, particularly among men above 60 years of age, remains a primary growth driver for the prostate cancer diagnosis and treatment market. Demographic shifts toward an aging population are directly increasing the patient pool requiring routine screening, confirmatory diagnostics, and long-term therapeutic management. Clinical guidelines in several countries recommend regular prostate-specific antigen testing and digital rectal examination for high-risk groups, supporting consistent diagnostic volumes. Improvements in laboratory accuracy, biomarker validation, and imaging integration are strengthening early-stage detection rates. Earlier diagnosis is leading to higher treatment initiation, thereby sustaining demand across hormonal therapy, radiation therapy, chemotherapy, immunotherapy, and targeted therapy segments.

Advancements in Therapeutic Innovation and Clinical Infrastructure

Continuous advancement in treatment innovation and precision oncology represents another major driver for market expansion. Pharmaceutical companies are expanding pipelines focused on next-generation hormonal agents, radioligand therapies, and immune-based approaches designed to improve survival outcomes in advanced and metastatic cases. Regulatory approvals for novel targeted therapies are broadening the available treatment landscape and encouraging earlier adoption in clinical practice. Expansion of specialized oncology centers and improved access to reimbursement in key healthcare systems are increasing therapy uptake. Growing clinical research activity and participation in oncology trials are accelerating the introduction of differentiated therapeutic options, reinforcing sustained market growth.

Market Segmentation

• Based on diagnostic technique, the market is segmented into prostate-specific antigen test and digital rectal exam.
• Based on therapy, the market is segmented into hormonal therapy, chemotherapy, immunotherapy, radiation therapy, and targeted therapy.

Precision Imaging Driving Early Detection

PSMA-based PET imaging has emerged as one of the most widely adopted diagnostic sub-segments within the UK prostate cancer diagnostic landscape due to its ability to detect tumors and metastatic lesions with significantly higher sensitivity than conventional imaging techniques. Hospitals and specialty cancer centers increasingly rely on this modality for staging and therapy planning, which has strengthened its clinical adoption across the country. The growing incidence of prostate cancer and the push for earlier detection programs continue to accelerate demand for advanced imaging diagnostics. Technology providers such as Siemens Healthineers, GE HealthCare, and Philips Healthcare remain key suppliers of PET-CT systems and radiotracers used in PSMA imaging. Research activity in theranostics and tracer development is also expanding the diagnostic accuracy and clinical utility of these tools. The segment is further supported by innovations in PSMA-targeted tracers that enable clearer tumor visualization and more precise treatment selection.

Targeted Radioligand Therapy Gains Clinical Momentum

Radioligand therapy targeting prostate-specific membrane antigen represents one of the fastest-expanding therapeutic approaches in the UK prostate cancer treatment landscape. This therapy delivers radiation directly to cancer cells using isotopes such as Lutetium-177, minimizing damage to surrounding healthy tissues while improving treatment outcomes. Increasing acceptance of precision oncology and NHS support for advanced cancer therapies are accelerating the integration of these treatments into routine clinical practice. Pharmaceutical companies including Novartis, Bayer, and AstraZeneca are actively investing in radiopharmaceutical pipelines and clinical partnerships in the UK market. Recent developments around PSMA-targeted radioligand drugs, including therapies designed for metastatic and treatment-resistant disease stages, are expanding the eligible patient pool. Continuous research collaborations between biotech firms and academic institutions are also strengthening innovation and production capabilities in this segment.

Market Players Outlook

The major companies operating in the UK prostate cancer diagnostic and therapeutic market include Roche, Novartis, Pfizer, Johnson & Johnson, AstraZeneca, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In February 2026, Medequip announced a corporate charity partnership with Prostate Cancer UK. Funds raised during 2026 will support prostate cancer awareness initiatives and research into improved diagnostics and treatments.

• In December 2025, Prostate Cancer UK announced a £2 million ($2.64 million) clinical trial to test a new drug called SX-682 for advanced (stage 4) prostate cancer.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the UK prostate cancer diagnostic and therapeutic market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.